Vanguard Russell 2000 U.S. Small-Cap UCITS ETF
(VRSA) Vanguard Russell 2000 U.S. Small-Cap UCITS ETF - (USD) Accumulating
Related Documents
About this fund
Fund objectives
- In seeking to achieve its investment objective, the Fund aims to provide a return which, before the application of fees and expenses, is similar to the return of the Index.
- The Fund employs a passive management – or indexing – investment approach, through physical acquisition of securities, and seeks to track the performance of the Russell 2000® Index (the “Index”).
- The Index measures the performance of the small-cap segment of the US equity universe. The Index is a subset of the Russell 3000® Index which is designed to represent approximately 98% of the investable US equity market. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership.
- The Fund attempts to: 1. Track the performance of the Index by fully replicating the Index, so that the Fund invests in all, or substantially all, of the constituents of the Index, making the weight of such investments approximate to those of the Index, to the extent practicable. 2. Remain fully invested except in extraordinary market, political or similar conditions where the Fund may temporarily depart from this investment policy to avoid losses.
Fund facts
Share class inception
Jul 07 2026
Listing date
Jul 09 2026
Investment structure
Irish UCITS
Share class assets'
Total assets
Risk indicator
Strategy
Index
Asset class
Equity
Investment Method
Physical
Index ticker
RU2000N
Benchmark
Russell 2000 Index
Dividend Schedule
—
Tax status
Austria, Germany, Switzerland and United Kingdom
Domicile
Ireland
Legal Entity
Vanguard Funds PLC
Siefores Approved
No
The value of investments, and the income from them, may fall or rise and investors may get back less than they invested.
Vehicles authorized for Siefores are those that meet the criteria issued by the CAR (Risk Analysis Committee) and are reviewed by an independent expert.
Performance
Risk and Volatility
-
Sorry, this information is not available yet. It will display a year after inception date.
Portfolio data
Characteristics
| Fundamentals | Fund | Benchmark | As at |
|---|---|---|---|
| Number of stocks | 1,972 | 1,962 | Sep 30 2026 |
| Median market capital | 3.5 B | 3.5 B | Oct 31 2026 |
| 15.9 x | 16.0 x | Oct 31 2026 | |
| 2.0 x | 2.0 x | Oct 31 2026 | |
| 7.1% | 7.1% | Oct 31 2026 | |
| 8.9% | 9.0% | Oct 31 2026 | |
| Portfolio turnover rate | — | — | — |
Market allocation
As at Sep 30 2026
| Country | Region | Fund | Benchmark | Variance +/- |
|---|---|---|---|---|
| United States of America | North America | 97.44% | 97.10% | 0.34% |
| Other | Other | 0.93% | 2.56% | -1.63% |
| Canada | North America | 0.71% | — | — |
| United Kingdom | Europe | 0.32% | — | — |
| Norway | Europe | 0.18% | — | — |
| Brazil | Emerging Markets | 0.15% | 0.15% | 0.00% |
| Panama | Emerging Markets | 0.06% | 0.05% | 0.01% |
| Israel | Middle East | 0.05% | 0.04% | 0.01% |
| Singapore | Pacific | 0.05% | 0.05% | 0.00% |
| Ireland | Europe | 0.04% | — | — |
| Greece | Europe | 0.02% | — | — |
| Italy | Europe | 0.02% | — | — |
| Australia | Pacific | 0.02% | — | — |
| South Africa | Emerging Markets | 0.01% | — | — |
| China | Emerging Markets | 0.00% | — | — |
Top 10 Holdings
As at Sep 30 2026
| Holding name | % of market value | Sector | Region | Market value | Shares |
|---|---|---|---|---|---|
| Twist Bioscience Corp | 0.43075% | Health Care | US | $61,063.84 | 316 |
| Moog Inc | 0.36866% | Industrials | US | $52,261.39 | 137 |
| JFrog Ltd | 0.35664% | Technology | US | $50,557.84 | 521 |
| 10X Genomics Inc | 0.35631% | Health Care | US | $50,511.24 | 559 |
| UMB Financial Corp | 0.32374% | Financials | US | $45,893.53 | 353 |
| BrightSpring Health Services Inc | 0.32066% | Health Care | US | $45,456.75 | 801 |
| Glaukos Corp | 0.31851% | Health Care | US | $45,152.25 | 275 |
| Viasat Inc | 0.30632% | Telecommunications | US | $43,424.46 | 617 |
| Hut 8 Corp | 0.29943% | Technology | US | $42,447.30 | 493 |
| Cytokinetics Inc | 0.29895% | Health Care | US | $42,380.13 | 643 |
Prices and distribution
Prices
NAV Price (USD)
$93.83
USDChange
-$0.29-0.31% As at Nov 13 2026
Market price (USD)
$93.57
Change
-$1.63-1.71% As at Nov 13 2026
NAV 52-week high
$102.94
As at Nov 14 2026
Market price 52-week high
$102.67
As at Nov 14 2026
NAV 52-week low
$91.46
As at Nov 14 2026
Market price 52-week low
$92.12
As at Nov 14 2026
NAV 52-week difference
$11.48
Change
+11.15% As at Nov 14 2026
Market price 52-week difference
$10.55
Change
+10.28% As at Nov 14 2026
Outstanding shares
153,826
As at Oct 31 2026
Discount
-$0.27
Change
-0.29% As at Nov 13 2026
Historical Prices
-
Inception date
Jul 07 2026
Listing date
Jul 09 2026
| Date | NAV (USD) | Market price (USD) |
|---|---|---|
| Nov 13 2026 | $93.8332 | $93.5650 |
| Nov 12 2026 | $94.1279 | $95.1900 |
| Nov 11 2026 | $95.7123 | $95.7050 |
| Nov 10 2026 | $94.8770 | $94.3350 |
| Nov 09 2026 | $95.5214 | $95.0150 |
| Nov 06 2026 | $92.6032 | $92.3200 |
| Nov 05 2026 | $91.7805 | $93.4650 |
| Nov 04 2026 | $96.0484 | $95.3300 |
| Nov 03 2026 | $94.5530 | $94.9700 |
| Nov 02 2026 | $94.3124 | $95.4450 |
Purchase information
Currencies and stock exchanges
Listed currencies: MXN, USD, EUR, GBP
Base currency:USD
Exchanges: Bolsa Mexicana De Valores, SIX Swiss Exchange, NYSE Euronext - Amsterdam, Borsa Italiana S.p.A., Deutsche Boerse, London Stock Exchange